510(k) Report

510(k) · Cleared

Cleared

Diazyme Human Kappa Free Light Chain Assay; Diazyme Human Lambda Free Light Chain Assay

K181438510(k) SpecialCleared Jun 26, 201825-day reviewClass II21 CFR 866.5550

Data to Oct 25, 2026 (FDA decisions) Oct 12, 2026 (recalls) Sep 30, 2026 (MAUDE) refreshed weekly, last Nov 3, 2026

Diazyme Laboratories, Inc. · DFH Kappa, Antigen, Antiserum, Control

Cleared on Jun 26, 2018 after a 25-day review. FDA’s file for it is a 510(k) statement, which names no predicate.

Decided
Jun 26, 2018
Review
25 days
Class
Class II
Product code
DFH
Recalls
None
Predicates
0

FDA’s file for it is a 510(k) statement, which names no predicate.

FIG. 1 — Lineage of K181438Source: FDA 510(k) database · How lineage is built

Get the monthly Device Review Tracker

Notable FDA decisions, review times and new Class I recalls. See an issue.

Sources: FDA 510(k) database (decision fields), the FDA 510(k) statement (indications), FDA recall and enforcement reports, and MAUDE; processed by 510(k) Report. Verify on FDA.gov · Methodology and accuracy.

Planning a device in DFH? A 510(k) Report weighs predicate choices, recall history and review times for a new device like this one.

Top candidate predicates for a new DFH device

  1. #1 K253358 Diazyme Human Kappa (k) Free Light Chain…score 10.5 · 1 generation · no Class I recall
  2. #2 Held for the reportin the report
  3. #3 Held for the reportin the report
Get a 510(k) Report

What was it cleared against?

FDA’s file for it is a 510(k) statement, which names no predicate.

What descends from it?

No later submission names this one as a predicate yet.

Has anything in its family been recalled? (0 Class I)

No FDA recall names this device.

No ancestor or descendant has a Class I recall.

How does its category compare?

All DFH devices

DFH Kappa, Antigen, Antiserum, Control: FDA decisions, review times, recalls and adverse event reports over 20 years. 2018, this device’s year, is highlighted.

FDA decisions per year · DFH

2in 2025

2007: 22008: 12009: 12013: 12015: 12016: 12017: 12018: 32019: 12021: 22022: 42024: 22025: 2
2007high 4 (2022) · low 0 (2010)2026

2026 to Oct 25, outlined.

Median 510(k) review, days · DFH

340in 2022

2018: 90 days median2022: 340 days median
2007high 340 (2022) · low 90 (2018)2026

Receipt to decision; years with fewer than 3 clearances left blank.

Recalls per year · DFH

1in 2020

2020: 1
2007high 1 (2020) · low 0 (2007)2026

Class I (0 since 2007) Class II/III not classified

Adverse event reports per year · DFH

10in 2025

2017: 12019: 42021: 12022: 112023: 32024: 132025: 10
2007high 13 (2024) · low 0 (2007)2025

MAUDE reports naming product code DFH, not matched to any one device; reports are not rates.

View these four charts as a table
YearDecisionsMedian 510(k) review, daysRecalls (Class I)MAUDE reports
20072—00
20081—00
20091—00
20100—00
20110—00
20120—00
20131—00
20140—00
20151—00
20161—00
20171—01
201839000
20191—04
20200—10
20212—01
20224340011
20230—03
20242—013
20252—010
20260—0—

What is it indicated for?

The Diazyme Human Kappa Free Light Chain Assay is intended as a latex particle enhanced immunoturbidimetric assay for the quantitative determination of Kappa Free Light Chain (FLC) concentration in serum on Hitachi 917 analyzers. The measurement of Kappa FLC in conjunction with Lambda FLC aids in the diagnosis of multiple myeloma in conjunction with other laboratory findings. For in-vitro diagnostic use only. The Diazyme Human Lambda Free Light Chain…

Read the full statement (124 words)

The Diazyme Human Kappa Free Light Chain Assay is intended as a latex particle enhanced immunoturbidimetric assay for the quantitative determination of Kappa Free Light Chain (FLC) concentration in serum on Hitachi 917 analyzers. The measurement of Kappa FLC in conjunction with Lambda FLC aids in the diagnosis of multiple myeloma in conjunction with other laboratory findings. For in-vitro diagnostic use only.

The Diazyme Human Lambda Free Light Chain Assay is intended as a latex particle enhanced immunoturbidimetric assay for the quantitative determination of Lambda Free Light Chain (FLC) concentration in serum on Hitachi 917 analyzers. The measurement of Lambda FLC in conjunction with Kappa FLC aids in the diagnosis of multiple myeloma in conjunction with other laboratory findings. For in-vitro diagnostic use only.

Indications for use as stated in the FDA 510(k) statement.

Cite this page

510(k) Report. “K181438: Diazyme Human Kappa Free Light Chain Assay; Diazyme Human Lambda Free Light Chain Assay.” Lineage record from FDA 510(k) data and the FDA summary. Updated Nov 3, 2026. Accessed Nov 6, 2026. https://510kreport.com/device/K181438

Report an extraction error

Tell us what is wrong; we check it against the FDA summary.

Are you the manufacturer?

Send a correction or an update to this page, for example a newer model or a public statement about a recall.

Record history
  • FDA decision record loaded May 2, 2026
  • Summary read Oct 13, 2026 (extraction version 9eaa42aa01ed)
  • Page last updated Nov 3, 2026